Kaiser Permanente’s Institute for Health Policy invites you to join a two-part virtual forum examining racial equity in the drug development system, from research all the way through to access. This first conversation on December 7 will specifically explore racial inequities in drug investment and research and identify new directions for the future.
The Medicaid Drug Rebate Program (MDRP) requires pharmaceutical manufacturers to issue rebates to Medicaid for covered outpatient drugs. When they offer prescription drug benefits, Medicaid programs must cover nearly all drugs, potentially reducing Medicaid’s leverage to negotiate discounts. Policymakers created…
Pharmaceutical marketing aims to shape both patient and clinician perceptions about a drug’s benefit and can significantly impact patient and clinician decisions that then affect outcomes, in addition to draining government and health care system resources. This paper describes the…
What good is a life-saving, ground-breaking treatment that patients and the health care system cannot access or afford? This question was front of mind for me during last fall’s Brocher Foundation meeting about cell and gene therapies: cutting-edge therapies that…
Last month, I was pleased to speak at the Institute for Health Policy forum that delved into a critical topic in the drug pricing dialogue: drug value. When I arrived in Washington, D.C., I was struck by how far we’ve…
As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions. This paper…
Over the past decade, U.S. drug prices have risen to unsustainable levels, threatening to cripple our health care system. Potential solutions have largely focused on how to finance and cover these high prices. But there’s another conversation emerging — one…
This event brought together leaders from across sectors to advance the conversation on defining and assessing drug value and elevate policy opportunities that encourage a value-based approach to drug pricing.
Patents are in the news as Congress considers legislation to address patent abuses and anticompetitive behavior by the pharmaceutical industry. If you’re tuning into these issues for the first time (or even the second or third) you’ll notice that there…
Over the course of the past year, we’ve seen renewed interest from federal policymakers in curbing pharmaceutical industry marketing practices that increase drug spending for patients, taxpayers, and the health care system as a whole. This week, the U.S. Department…